Pharmerica (PMC) Tops Q4 EPS by 4c; Guides FY16 EPS Below Expectations

Pharmerica (NYSE: PMC) reported Q4 EPS of $0.45, $0.04 better than the analyst estimate of $0.41. Revenue for the quarter came in at $520.6 million versus the consensus estimate of $506.4 million.

GUIDANCE:

Pharmerica sees FY2016 EPS of $1.95-$2.05, versus the consensus of $2.31. Pharmerica sees FY2016 revenue of $2.125-2.150 billion, versus the consensus of $2.11 billion.

For earnings history and earnings-related data on Pharmerica (PMC) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Titan Machinery (TITN) Misses Q2 EPS by 5c ; Offers Guidance
• Dollar General (DG) Tops Q2 EPS by 48c, Beats on Revenue; Offers FY27 EPS Guidance